Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Genmab
Biotech
Genmab inks $1.8B ProfoundBio buyout for would-be Elahere rival
The deal will give Genmab control of a midphase antibody-drug conjugate that could compete against AbbVie’s Elahere.
Nick Paul Taylor
Apr 3, 2024 5:32am
Genmab's growth plan entails partnering less, owning more: CEO
Mar 14, 2024 9:40am
Argenx, Genmab join forces to expand into new therapeutic areas
Apr 17, 2023 6:20am
AbbVie's Roche-rivaling bispecific gets FDA priority review
Nov 21, 2022 9:45am
AbbVie lays down marker in fiercely competitive bispecific niche
Jun 13, 2022 8:25am
Chasing Roche, AbbVie posts data on CD20 blood cancer bispecific
Apr 14, 2022 7:10am